Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuyi Mingmu Pian (初一明目片) is a Traditional Chinese Medicine (TCM) herbal formulation developed and marketed by Shaanxi Momentum Pharmaceutical (Shaanxi Momentum Qixuehe Pharmaceutical Co., Ltd.). It is formulated as an oral tablet and is approved for use in China. The medication is indicated for conditions characterized by "wind-fire" affecting the head and eyes, including eye swelling, pain, nebula (corneal opacity), and photophobia with tearing. According to TCM principles, its mechanism of action involves clearing heat, purging fire, and dispelling wind to resolve corneal cloudiness. As a complex herbal formulation, its specific molecular targets and pharmacological mechanisms in Western medical terms are not defined.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuyi Mingmu Pian.